Fulcrum Therapeutics, Inc. (FULC) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to Fulcrum's Therapeutics Second Quarter 2024 Financial Results and Business Update Conference Call. Currently, all participants are on a listen-only mode. This call is being webcast live and can be accessed on the investor section of Fulcrum's website at www.fulcrumtx.com and is being recorded. Please be reminded the remarks during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. May include statements about the company's future expectations and plans, timelines, and financial projections. While these forward-looking statements represent full-time views as of today, this should not be relied upon as representing the company's views in the future. Fulcrum may update these statements in the future, but is not taking on an obligation to do so. Please refer to Fulcrum's most recent filings with the Securities and Exchange Commission for discussion of certain risks and uncertainties associated with the company's business. Meeting today will be Alec Sapir, CEO and President of Fulcrum. Joining Alex on the call are Alan Musso, Chief Financial Officer, Dr. Pat Horn, Chief Medical Officer, and Dr. Lynn Fazer, Senior Vice President of Development. After providing updates on our key programs, there will be a brief Q&A in which Alex, Alan, Pat, and Lane will be available to answer your questions. With that, it's my pleasure to turn the call over to Alex. That's great. Thank you, Lisa. And good morning, everyone. And thanks to all of you for joining us for our second quarter conference call. We've organized today's call to provide you with updates on recent progress and upcoming milestones for our two clinical stage assets, Los Mapamad and Pociradir. And after a brief introductio...